non-infectious uveitis
Ophthalmology · 2017–2024
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| adalimumab Treatment of vision-threatening non-infectious uveitis in adult and paediatric patients who have had an inadequate response to corticosteroids, are in need of… | Mar 2024 | Recommended with restriction | 35 individuals Australian Rheumatology Association · Juvenile Arthritis Foundation Australia |
| adalimumab Treatment of non-infectious intermediate, posterior or panuveitis in patients who have failed corticosteroid and immunomodulatory therapy, require emergency… | Mar 2017 | Not recommended | input received |
Who spoke
Australian Rheumatology Association · Juvenile Arthritis Foundation Australia
What the PBS pays
$242M in government benefit over 2024–25, across 411,820 services.
This is spend on the medicines considered for this condition, not spend on the disease. A medicine used for several conditions is counted in full under each, so figures across conditions add to more than national PBS expenditure.
| Medicine | Government benefit |
|---|---|
| adalimumab | $241.9M |
Appraised elsewhere
NICE, in England and Wales, has appraised 2 technologies for this condition, recommending 2 . A different committee, a different population and a different price: this is what has been looked at there, not a verdict on what happened here.
| Technology | Appraisal | Outcome | Date |
|---|---|---|---|
| fluocinolone acetonide intravitreal implantFluocinolone acetonide intravitreal implant for treating recurrent non-infectious uveitis | TA590 | recommended restricted | 2019-07 |
| adalimumab and dexamethasoneAdalimumab and dexamethasone for treating non-infectious uveitis | TA460 | recommended restricted | 2017-07 |
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 2 of 2 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.